Next Article in Journal
Metagenomic Profile of Bacterial Communities of Hyalomma scupense and Hyalomma asiaticum Ticks in Kazakhstan
Previous Article in Journal
Spotted Fever Rickettsioses in Panama: New Cases and the Gaps That Hinder Its Epidemiological Understanding
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 14
Issue 10
10.3390/pathogens14101007
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis

by
Lukus Berber
,
Olivia Foy
,
Jesus Cantu, Jr.
and
Eli D. Ehrenpreis
*
Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
*
Author to whom correspondence should be addressed.
Pathogens 2025, 14(10), 1007; https://doi.org/10.3390/pathogens14101007
Submission received: 1 August 2025 / Revised: 12 September 2025 / Accepted: 3 October 2025 / Published: 6 October 2025
(This article belongs to the Section Viral Pathogens)
Browse Figures
Versions Notes

Abstract

Background: HPV infections with high-risk subtypes are a risk factor for developing cervical and anal cancer. Despite HPV vaccination, the incidence of cervical and anal cancer is increasing. There has been substantial research regarding the benefits of screening men who have sex with men (MSM) and those diagnosed with HIV for anal HPV and dysplasia, but little data exists for women diagnosed with cervical cancer. Methods: We constructed a Markov model in Python 3.13 to simulate the outcomes and financial impact of screening women newly diagnosed with cervical cancer for anal HPV and dysplasia. Two matrices were used to represent the screened group and the unscreened group. In the screening group, all women received initial anal HPV screening and high-resolution anoscopy with biopsy. If biopsy results confirmed HSIL, each would receive treatment with electrocautery. The screening group would also undergo annual surveillance and follow-up treatment as necessary. In the unscreened group, women did not receive screening or treatment, and the disease process was allowed to progress naturally. Results: The initial cohort consisted of 5555 women diagnosed with cervical cancer and concurrent anal HPV. The incidence of anal cancer in the screening group was 271 vs. 375 in the unscreened group after three years, 642 vs. 1236 after ten years, and 863 vs. 2039 after twenty years. Moreover, anal cancer deaths were 1236 in the screening group vs. 9041 in the unscreened group after 10 years and 31,118 vs. 51,553 after twenty years. The screened group saved 330.1 million dollars after ten years and 1.33 billion dollars after twenty years when compared to the unscreened group. Over the life of the study, the screened group would also accrue 102,000 discounted QALYs when compared to the unscreened group. Conclusions: Our model strongly suggests that screening women diagnosed with cervical cancer for anal HPV and treating anal dysplasia leads to less anal cancer, less deaths from anal cancer, less economic impact on the healthcare system, and more QALYs for patients.

1. Introduction

Human papillomavirus (HPV) is a single-stranded DNA virus from the Papillomaviridae family [1]. Many HPV infections are asymptomatic and 90% resolve spontaneously within two years. While typically self-limiting, persistent infection with high-risk HPV subtypes, particularly types 16 and 18, can lead to malignancy, most commonly cervical cancer. It is estimated that 620,000 new HPV-related cancers occur annually throughout the world [2]. Women with cervical HPV infection are approximately seven times more likely to have concurrent anal HPV infection [3]. The International Anal Neoplasia Society (IANS) has classified women with a history of cervical cancer to be at a higher risk for anal cancer [4]. Studies in men who have sex with men (MSM) demonstrate that targeted HPV screening can reduce anal cancer incidence [5]. Women diagnosed with cervical cancer are not routinely screened for anal HPV at this time and we believe this vulnerable population would benefit from further research. Furthermore, as the population ages without the benefit of the HPV vaccine, anal cancer is anticipated to become more common in women older than 65 years of age [6]. Our study uses a cost and quality of life (QOL) model to evaluate the potential benefits of screening for anal HPV and anal dysplasia among women who are newly diagnosed with cervical cancer.

2. Methods

We created a dynamic Markov chain model to simulate disease progression and outcomes over 20 years in women newly diagnosed with cervical cancer who either underwent or did not undergo screening for anal HPV. We chose a Markov model as a decision tree to characterize future occurrences based on the present state. Our model was designed to predict future occurrences with reasonable accuracy, such as tumor incidences and deaths, based on assumptions regarding the initial state of the system and the annual rates of change between the various states. [7]. A comprehensive, reproducible literature search with predefined keywords and MeSH terms in PubMed/MEDLINE and related databases were utilized for the model components (initial inputs and annual rates of change between states) for the model (Table 1).

2.1. Model Development

A Markov model was constructed in Python to replicate the STELLA-based simulation originally developed by Ehrenpreis et al. (2018), which evaluated the clinical and economic impact of anal cancer screening in women newly diagnosed with cervical cancer (Figure 1) [21]. The model was reformulated using matrix algebra to simulate annual transitions between health states over a 20-year time horizon. The model includes five mutually exclusive health states: (1) No Dysplasia, (2) Low-Grade Dysplasia (LGD), (3) High-Grade Dysplasia, (4) Anal Cancer, and (5) Death. At each yearly cycle, individuals may remain in their current state, progress to a more advanced state, regress to a less advanced state, or transition to death. Two transition matrices were used: one for a population that receives no screening or treatment (unscreened), and one for a population of women with newly diagnosed cervical cancer that receives screening and treatment for HGD (screened).
Dashed arrows represent cervical cancer-related mortality from any non-cancer state, with risk reduced under screening. Screening is also assumed to reduce the probability of progression from HGD to Anal Cancer. All HPV-positive individuals remain under continuous surveillance and are not modeled to return to an HPV-negative or untested state. The Death state absorbs these cases.
In the screened population, all women undergo initial HPV screening and high-resolution anoscopy with biopsy. If HGD is detected, electrocautery treatment is administered with a base-case cure rate of 95.0%. Individuals in the screened group receive annual surveillance and undergo repeat treatment as needed. In the unscreened population, no screening or treatment is performed, and disease progresses naturally based on previously published progression rates.
The initial model cohort consisted of 5555 women with concurrent cervical cancer and anal HPV infection. This estimate was calculated by applying an anal HPV prevalence rate of 48.3% to 13,820 projected U.S. cervical cancer cases. Baseline distribution across health states was based on anal cytology data from prior studies: 68.0% were placed in the No Dysplasia state, 20.0% in LGD, 9.97% in HGD, and 2.03% in Anal Cancer [22]. No individuals began in the state of death.
At each time point, the distribution of the cohort was updated through matrix multiplication of the current state vector and the corresponding transition matrix. This process was applied for 20 cycles, and annual outputs were recorded. The Python implementation utilized NumPy and Pandas, programs designed to analyze large exponential arrays of data and organize them in data frames, while Matplotlib 3.10.0 and Seaborn 0.13.2 were used to generate visual representations of the data.

2.2. Cost Analysis

Cost estimates were obtained from the prior literature and Medicare reimbursement data [19], adjusted to 2025 USD using a 2.05% annual inflation rate [23]. The model included costs associated with HPV screening, cytology, biopsy, HGD treatment, surveillance, and anal cancer management.
Women in the screened group incurred the costs of initial screening, diagnostic evaluation, treatment, and surveillance. Costs were assigned to patients based on their health state each year. In contrast, women in the unscreened group did not incur costs related to screening or treatment of dysplasia treatment found on initial screening but were assigned costs if they developed anal cancer. Total and per-patient costs were calculated for both groups annually and cumulatively over the 20-year simulation horizon.

2.3. Sensitivity Analysis

To assess the impact of uncertainty in treatment efficacy, a one-way sensitivity analysis was performed on the cure rate of anal high-grade dysplasia (HGD) following electrocautery. Cure rates varied from 38% to 98%, consistent with published clinical outcomes [22].
For each value, the model estimated cumulative costs and quality-adjusted life years (QALYs) over 5-, 10-, and 20-year time horizons in both screened and unscreened cohorts. Incremental cost-effectiveness ratios (ICERs) were then calculated as the difference in costs divided by the difference in QALYs between the two strategies. Results are reported as cost per QALY gained, allowing for evaluation of cost-effectiveness across a plausible range of treatment efficacies.

2.4. Outcomes Determined from the Model

The simulation generated yearly and cumulative estimates for clinically relevant outcomes across the 20-year time horizon. These included the number of new and total cases of anal cancer, deaths attributable to anal cancer, and the aggregate healthcare costs incurred within each group. Model outputs were also used to assess comparative effectiveness by calculating cost per cancer prevented, cost per death averted, and cost per quality-adjusted life year (QALY) gained. These metrics were derived from the longitudinal differences observed between the screened and unscreened populations.
The full range of outcomes produced by the model informed the evaluation of whether routine anal cancer screening and treatment offer a measurable benefit in this high-risk cohort. The rates of histological progression and regression from normal to low-grade dysplasia, high-grade dysplasia, and anal cancer were incorporated into the model [10,11,22]. Some model assumptions were obtained from studies focusing on MSM due to insufficient data in some cases when data in women with cervical cancer were unavailable. Model-generated outcomes included anal cancer incidence, anal cancer-related mortality, quality-adjusted life years (QALYs), total and incremental costs, and cost per QALY gained. QALYs were calculated on a 1-0 scale where 1 is perfect health and 0 represents death. The average quality of life is then multiplied by the years lived after medical intervention to reach QALYs. Our model relies on quality-of-life surveys from cervical and anal cancer patients [5,24]. The overall benefit of the proposed screening program is highly dependent on the effectiveness of curative treatment for anal high-grade dysplasia and therefore a sensitivity analysis was performed for a range of potential cure rates for electrocautery treatment of anal high-grade dysplasia. Outcomes were determined for cure rates of 38%, 48%, 58%, 78%, 88%, and 98%. These factors determined by the simulation performed provide the rationale for screening this patient population. The code for the model and the calculations performed are seen in Supplementary File S1.

3. Results

The updated model shows that within the first three years, the difference in cases begins to emerge, with 375 cases in the unscreened group vs. 271 in the screened group. This gap continues to widen over time. By the tenth year, 1236 cumulative anal cancer cases are predicted in the unscreened group vs. 642 cases in the screened group. At 20 years, 2039 cumulative cases occur in the unscreened population compared to 863 cases in the screened population, preventing a total of 1176 cases through screening (Figure 2a; Table 2).
Differences in mortality follow a similar trajectory. Anal cancer deaths are reduced from 16,248 in the unscreened population to 9041 in the screened group at 10 years, and from 51,553 to 31,118 deaths over the 20-year period—representing 20,435 lives saved with screening (Figure 2b; Table 2).
There were ~777,000 discounted QALYs compared to ~675,000 QALYs in the unscreened group (Figure 3a). Cumulative discounted costs were also significantly lower in the screened population, totaling USD 2.02 billion vs. USD 3.36 billion in the unscreened group (Figure 3b, Table 3). Thus, screening resulted in savings of USD 1.33 billion and an additional 102,000 discounted QALYs.Per-patient cost-effectiveness outcomes are also favorable. At 20 years, the cost per anal cancer case prevented was USD 109,222, the cost per anal cancer death prevented was USD 7649, and the cost per quality-of-life year saved was USD 9610 (Table 3).
Annual costs also demonstrate early and sustained savings. At 5 years, the screened group had accrued 68.9 million USD less in total costs compared to the unscreened group. These savings increase to USD 330.1 million at 10 years and USD 1.33 billion at 20 years (Table 3).
To assess the robustness of these findings, a one-way sensitivity analysis was performed on the cure rate of anal high-grade dysplasia following electrocautery, ranging from 38% to 98% based on published outcomes. At all tested cure rates and across 5-, 10-, and 20-year time horizons, screening consistently resulted in lower costs and better health outcomes compared to no screening, confirming its status as a cost-saving strategy. For example, at a cure rate of 38%, the cost per QALY gained was USD 2049 at 20 years and improved further to USD 9646 at a 98% cure rate (Table 4).
Although the incremental cost-effectiveness ratios (ICERs) are presented as absolute values in Table 4, all estimates reflect net cost savings with screening. These savings were evident as early as 5 years, where per-QALY costs ranged from USD 3622 to USD 13,234 and became more pronounced over time. Over 10 years, ICERs ranged from USD 3050 to USD 11,909. These results demonstrate that screening remains economically dominant across a wide range of plausible treatment efficacies (Table 4).

4. Discussion

The incidence of anal cancer between 2017 and 2021 has increased by 2.9% for women and 1.6% for men [6]. Moreover, according to Cooley et al., cervical cancer deaths are also on the rise in women older than 65 [25]. Screening for cervical as well as anal HPV are considered cost-effective methods to prevent cervical and anal cancer. However, at present, routine screening for anal HPV is only recommended for MSM, patients with HIV, and women diagnosed with vulvar cancer or vulvar HSIL [26]. In 2024, IANS, International Anal Neoplasia Society, made an additional recommendation to include only discretional screening of women with cervical cancer or HSIL [4]. It is important to recognize that while we predominantly draw data related to anal HPV infections from populations of patients with HIV, other immunosuppressed patients have increased risk of developing anal cancer. T-cell surveillance is the primary defense mechanism against dysplasia. Anal and cervical cancer are particularly tied to immunosuppression as both cancers are primarily caused by chronic HPV infection. Chronic HPV infection and failure to clear HPV from infected tissues appear to be the important mechanisms by which HPV causes epithelial dysplasia. A large cohort study in Denmark found that patients with HIV infection, those receiving solid organ transplants, and patients with hematologic malignancies were at higher risk of developing anal cancer [27]. However, patient groups recommended for anal HPV screening are not inclusive for all high-risk groups. For example, women without HIV are not included in screening guidelines for anal HPV and anal cancer [5]. In our view, women newly diagnosed with cervical cancer represent a potential group for cost-effective screening [21].
There is substantial precedence for the use of Markov models in medicine to help reliably predict disease progression, cost effectiveness, and patient outcomes [28,29]. Our modeled screening program suggests there are benefits to screening women with cervical cancer for anal HPV. By conducting minimally invasive anal HPV screening and anal cytology in the setting of HPV infection, fewer women developed anal cancer, fewer women died of anal cancer, and women had a higher quality of life over the time of the study compared to women who were not screened. Moreover, the overall cost of screening and prevention of anal cancer was lower in the screened vs. unscreened group, where treatment of anal cancer, adjusted for inflation [19], superseded screening costs.
Screening women with cervical cancer for anal HPV meets appropriateness criteria for a screening program; as anal cancer is well understood, it is associated with high mortality, and primary interventions are not prohibitively costly [30]. Sampling of the anal epithelium can easily be performed in an office setting or during endoscopy [31]. Interventions on anal epithelial lesions such as hyfrecation can be completed without general anesthesia and are considered low-risk [12]. Moreover, early interventions on anal epithelial lesions have been shown to reduce the risk of anal cancer [12].
QALYs are a particularly important part of the model as anal cancer treatment is associated with poor quality of life. Chemotherapy and radiation are classically associated with an array of debilitating side effects, but surgical excision for anal cancer can lead to fecal incontinence or even loss of the anus with a diverting colostomy. Anal cancer patients often score poorly on quality-of-life surveys and cite permanent changes to their bodies as the primary reason [32].
The Anal Cancer HSIL Outcomes Research (ANCHOR) study by Palefsky et al. compared treatment of anal HSILs to active monitoring amongst 4459 HIV-positive patients over seven years [22]. The phase three randomized control trial concluded that treatment of anal HSILs was associated with a rate of progression to anal cancer 57% lower than active monitoring with high-resolution anoscopy alone. The literature suggests around 48% of women with high-grade cervical epithelial lesions have concomitant anal HPV infections [12]. There is no study comparable to ANCHOR for women with cervical cancer (an HPV-related cancer), a group at high risk for the development of anal cancer. It is known that 48.3% of women with cervical cancer have anal HPV infection, the majority of these caused by high-risk neoplasm subtypes [12].
When we looked to our colleagues abroad, there is a general consensus, albeit based on limited data in many cases, that screening for anal cancer is not presently recommended with the exception being high-risk groups such as patients living with HIV. Scholefield et al., in the United Kingdom, discussed several limiting factors for screening including the degree of difficulty of identifying histopathology, side effects of intervention on anal lesions, and high recurrence rates after intervention [33]. However, there is promising data that topical cidofovir combined with electrocautery reduced rates of recurrence to zero [33]. Another limiting factor was presented by Li et al., from China, that clinicians skilled in performing high-resolution anoscopy are limited globally [34]. However, both Li and Scholefield mention that some of the data with which we rely for our recommendations is often limited by small sample sizes and unrepresentative patient populations. We agree with our colleagues that the existing data is insufficient, and we believe that patients would benefit from future clinical trials that include women diagnosed with cervical cancer.
It is important to address the limitations of our study. While the data presented in the study is promising, robust clinical trials are required to validate our findings. The data utilized in the model were retrospectively derived from high-quality studies. However, some model assumptions needed to be made from studies of patient groups other than women with cervical cancer. For example, data for the annual progression of anal HPV infection to some epithelial lesions was drawn from a study consisting entirely of MSM and bisexual men in the late 1990s [5] because of the limited existing information on histologic progression in women with anal HPV infections. Moreover, there is data amongst MSM and patients with HIV that indicates a high recurrence rate: 53% recurrence amongst HIV-negative patients and 61% amongst patients with HIV [35]. Our model assumes a 95% cure rate with intervention, which is appropriate given our model cohort has functioning immune systems, but does not presently address recurrent dysplasia or the requirement for repeat interventions. While Marks et al. does not include women diagnosed with cervical cancer specifically, which our model considers directly, it does provide a route for further analysis in the future [35]. Additionally, the literature suggests that while recurrence of dysplasia does occur after intervention, development of anal cancer thereafter is quite rare—around 1% [36]. The lack of women-focused data does, however, illuminate a core premise of this study—our model suggests women at high risk for anal HPV infection should be primary targets for future research. A fundamental assumption in this study is that chronic anal HPV infections with high-risk HPV subtypes lead to progression from LGD, then to HSIL, and finally to anal cancer. While it is known that extended activity of HPV oncogenes leads to DNA mutations and ultimately anal cancer [37], progression of epithelial lesions may follow a different pattern than our assumption in the model.
In summary, when women with a new diagnosis of cervical cancer are screened for anal HPV, evaluated for anal epithelial dysplasia, and treated for anal HSIL, they are less likely to develop anal cancer, less likely to die from anal cancer, and have a higher quality of life. Our model also predicts that the proposed screening program is cost-effective as screening saves an estimated cost saving per diagnosed anal cancer of USD 120,416 at 5 years, USD 117,506 at 10 years, and USD 109,922 at 20 years. The model strongly suggests that providers should be cognizant of the risk of anal HPV in women diagnosed with cervical cancer and investigate accordingly.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens14101007/s1, File S1: Replication of the Ehrenpreis Cost Model for Anal HPV (2025 Update).

Author Contributions

Conceptualization, E.D.E.; methodology, J.C.J.; software, J.C.J.; formal analysis, L.B., J.C.J. and E.D.E.; data curation, L.B., J.C.J., O.F. and E.D.E.; writing—original draft preparation, L.B.; writing—review and editing, L.B., O.F. and E.D.E.; supervision, E.D.E. All authors have read and agreed to the published version of the manuscript.

Funding

The authors declare that this study was conducted without any external financial support.

Institutional Review Board Statement

This study was conducted in accordance with ethical standards and guidelines. Where applicable, approval was obtained from the appropriate institutional review board (IRB) or ethics committee prior to initiation of the research.

Informed Consent Statement

Not Applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare that there are no conflicts of interest related to the content of this manuscript. No financial, personal, or professional affiliations influenced the design, conduct, analysis, or reporting of this research.

References

  1. Milner, D.A. Diagnostic Pathology: Infectious Diseases; Elsevier Health Sciences: Amsterdam, The Netherlands, 2015; p. 40. ISBN 978-0-323-40037-4. [Google Scholar]
  2. American Cancer Society. Cancer Statistics Center. Available online: https://cancerstatisticscenter.cancer.org/ (accessed on 16 July 2025).
  3. Hernandez, B.Y.; McDuffie, K.; Zhu, X.; Wilkens, L.R.; Killeen, J.; Kessel, B.; Wakabayashi, M.T.; Bertram, C.C.; Easa, D.; Ning, L.; et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol. Biomark. Prev. 2005, 14, 2550–2556. [Google Scholar] [CrossRef]
  4. Stier, E.A.; Clarke, M.A.; Deshmukh, A.A.; Wentzensen, N.; Liu, Y.; Poynten, I.M.; Cavallari, E.N.; Fink, V.; Barroso, L.F.; Clifford, G.M.; et al. The International Anal Neoplasia Society’s consensus guidelines for anal cancer screening. Int. J. Cancer 2024, 154, 1694–1702. [Google Scholar] [CrossRef]
  5. Goldie, S.J.; Kuntz, K.M.; Weinstein, M.C.; Freedberg, K.A.; Welton, M.L.; Palefsky, J.M. The Clinical Effectiveness and Cost-effectiveness of Screening for Anal Squamous Intraepithelial Lesions in Homosexual and Bisexual HIV-Positive Men. JAMA 1999, 281, 1822–1829. [Google Scholar] [CrossRef]
  6. Robinson, A.; Ehrenpreis, E.; Dang, N.; Virdi, R.; Lafazanos, Y. Analysis of temporal trends in anal cancer incidence by sex, age, and ethnicity, 2017–2021. In Proceedings of the Scientific Day, Advocate Aurora Health, Park Ridge, IL, USA, 21 May 2025. [Google Scholar]
  7. Bala, M.V.; Mauskopf, J.A. Optimal assignment of treatments to health states using a Markov decision model: An introduction to basic concepts. Pharmacoeconomics 2006, 24, 345–354. [Google Scholar] [CrossRef]
  8. Sehnal, B.; Dusek, L.; Cibula, D.; Zima, T.; Halaska, M.; Driak, D.; Slama, J. The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. J. Clin. Virol. 2014, 59, 18–23. [Google Scholar] [CrossRef]
  9. American Cancer Society. Key Statistics for Cervical Cancer. American Cancer Society. 2025. Available online: https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html (accessed on 16 July 2025).
  10. Cronin, B.; Bregar, A.; Luis, C.; Schechter, S.; DiSilvestro, P.; Pisharodi, L.; Sung, C.J.; Raker, C.; Clark, M.; Robison, K. Evaluation of anal cytology and dysplasia in women with a history of lower genital tract dysplasia and malignancy. Gynecol. Oncol. 2016, 141, 492–496. [Google Scholar] [CrossRef]
  11. Oon, S.-F.; Winter, D.C. Perianal condylomas, anal squamous intraepithelial neoplasms and screening: A review of the literature. J. Med. Screen. 2010, 17, 44–49. [Google Scholar] [CrossRef] [PubMed]
  12. Palefsky, J.M.; Lee, J.Y.; Jay, N.; Goldstone, S.E.; Darragh, T.M.; Dunlevy, H.A.; Palefsky, J.M. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N. Engl. J. Med. 2022, 386, 2273–2282. [Google Scholar] [CrossRef] [PubMed]
  13. Goldstone, S.E.; Uronis, H.E.; Deshmukh, A.A. Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in HIV-positive men who have sex with men. Clin. Infect. Dis. 2015, 61, 1527–1535. [Google Scholar] [CrossRef]
  14. National Cancer Institute. SEER Cancer Stat Facts: Anus, Anal Canal and Anorectum Cancer. Surveillance, Epidemiology, and End Results Program. Available online: https://seer.cancer.gov/statfacts/html/anus.html (accessed on 15 July 2025).
  15. National Cancer Institute. SEER Cancer Stat Facts: Cervix Uteri Cancer. Surveillance, Epidemiology, and End Results Program. Available online: https://seer.cancer.gov/statfacts/html/cervix.html (accessed on 16 July 2025).
  16. Social Security Administration. Actuarial Life Table, 2022, as Used in the 2025 Trustees Report. 2025. Available online: https://www.ssa.gov/oact/STATS/table4c6.html (accessed on 16 July 2025).
  17. Meunning, B.P. Cost-Effectiveness Analysis in Health, 3rd ed.; John Wiley & Sons: San Francisco, CA, USA, 2016. [Google Scholar]
  18. Owens, D.K. Interpretation of cost-effectiveness analyses. J. Gen. Intern. Med. 1998, 13, 716–717. [Google Scholar] [CrossRef] [PubMed]
  19. Centers for Medicare; Medicaid Services. Physician Fee Schedule Overview. Available online: https://www.cms.gov/medicare/physician-fee-schedule/search/overview (accessed on 5 July 2025).
  20. Deshmukh, A.A.; Chiao, E.Y.; Das, P.; Cantor, S.B.; Shete, S. Healthcare costs associated with anal cancer treatment: Evidence from a U.S. commercially insured population. Cancer Med. 2023, 12, 16923–16931. [Google Scholar] [CrossRef]
  21. Ehrenpreis, E.D.; Smith, D.G. Patients with newly diagnosed cervical cancer should be screened for anal human papilloma virus and anal dysplasia: Results of a pilot study using a STELLA computer simulation and economic model. Papillomavirus Res. 2018, 5, 38–45. [Google Scholar] [CrossRef]
  22. Shvetsov, Y.B.; Hernandez, B.Y.; McDuffie, K.; Wilkens, L.R.; Zhu, X.; Ning, L.; Killeen, J.; Kamemoto, L.; Goodman, M.T. Duration and clearance of anal human papillomavirus (HPV) infection among women: The Hawaii HPV cohort study. Clin. Infect. Dis. 2009, 48, 536–546. [Google Scholar] [CrossRef] [PubMed]
  23. US Bureau of Labor Statistics. Consumer Price Index (CPI). U.S. Department of Labor. Available online: https://www.bls.gov/cpi/ (accessed on 16 July 2025).
  24. Sauter, C.; Peeken, J.C.; Borm, K.; Diehl, C.; Münch, S.; Combs, S.E.; Dapper, H. Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer. Sci. Rep. 2022, 12, 4416. [Google Scholar] [CrossRef] [PubMed]
  25. Cooley, J.J.P.; Maguire, F.B.; Morris, C.R.; Parikh-Patel, A.; Abrahão, R.; Chen, H.A.; Keegan, T.H.M. Cervical cancer stage at diagnosis and survival among women ≥65 years in California. Cancer Epidemiol. Biomark. Prev. 2023, 32, 91–97. [Google Scholar] [CrossRef] [PubMed]
  26. American Association for Cancer Research. Cervical cancer stage at diagnosis and survival. Cancer Epidemiol. Biomark. Prev. 2023, 32, 91. [Google Scholar] [CrossRef]
  27. Sunesen, K.G.; Nørgaard, M.; Thorlacius-Ussing, O.; Laurberg, S. Immunosuppressive disorders and risk of anal squamous cell carcinoma: A nationwide cohort study in Denmark, 1978–2005. Int. J. Cancer 2010, 127, 675–684. [Google Scholar] [CrossRef]
  28. Silverstein, M.D.; Loftus, E.V.; Sandborn, W.J.; Tremaine, W.J.; Feagan, B.G.; Nietert, P.J.; Harmsen, W.S.; Zinsmeister, A.R. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999, 117, 49–57. [Google Scholar] [CrossRef]
  29. National Center for Biotechnology Information. Anal Cancer. In StatPearls; StatPearls Publishing: Tampa/St. Petersburg, FL, USA, 2019. Available online: https://www.ncbi.nlm.nih.gov/books/NBK543650/ (accessed on 16 July 2025).
  30. Gosens, K.C.; Richel, O.; Prins, J.M. Human papillomavirus as a cause of anal cancer and the role of screening. Curr. Opin. Infect. Dis. 2017, 30, 87–92. [Google Scholar] [CrossRef]
  31. Slama, J.; Sehnal, B.; Dusek, L.; Zima, T.; Cibula, D. Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion. Neoplasma 2015, 62, 308–314. [Google Scholar] [CrossRef]
  32. UK National Screening Committee. Criteria for Appraising the Viability Effectiveness Appropriateness of a Screening Programme, GOV. UK. Available online: https://www.gov.uk/government/publications/evidence-review-criteria-national-screening-programmes/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme (accessed on 29 September 2022).
  33. Scholefield, J.H.; Nugent, K.P. Anal Cancer: Position Statement of the Association of Coloproctology of Great Britain and Ireland. Color. Dis. 2011, 13 (Suppl. 1), 1–52. [Google Scholar] [CrossRef]
  34. Li, Y.; Pan, Q.; Li, Y.; Tang, L.; Ren, R. Chinese expert consensus on diagnosis and treatment of anal cancer. Glob. Community Med. 2024, 4, e000013. [Google Scholar] [CrossRef]
  35. Marks, D.K.; Goldstone, S.E. Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. J. Acquir. Immune Defic. Syndr. 2012, 59, 259–265. [Google Scholar] [CrossRef] [PubMed]
  36. Pineda, C.E.; Berry, J.M.; Jay, N.; Palefsky, J.M.; Welton, M.L. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: A ten-year experience. Dis. Colon Rectum 2008, 51, 829–837. [Google Scholar] [CrossRef] [PubMed]
  37. Benevolo, M.; Donà, M.G.; Ravenda, P.S.; Chiocca, S. Anal human papillomavirus infection: Prevalence, diagnosis and treatment of related lesions. Expert Rev. Anti-Infect. Ther. 2016, 14, 465–477. [Google Scholar] [CrossRef] [PubMed]
Pathogens 14 01007 g001
Figure 1. Markov model representing the progression and regression of anal HPV-related dysplasia among women with a history of cervical cancer.
Figure 1. Markov model representing the progression and regression of anal HPV-related dysplasia among women with a history of cervical cancer.
Pathogens 14 01007 g001
Pathogens 14 01007 g002
Figure 2. (a) Model-predicted cumulative cases of anal cancer over a 20-year period in women with a history of cervical cancer, comparing screened and unscreened populations. (b) Model-predicted annual incidence of new anal cancer cases over a 20-year period in women with a history of cervical cancer, comparing those undergoing screening for anal dysplasia with those not screened.
Figure 2. (a) Model-predicted cumulative cases of anal cancer over a 20-year period in women with a history of cervical cancer, comparing screened and unscreened populations. (b) Model-predicted annual incidence of new anal cancer cases over a 20-year period in women with a history of cervical cancer, comparing those undergoing screening for anal dysplasia with those not screened.
Pathogens 14 01007 g002
Pathogens 14 01007 g003
Figure 3. (a) Predicted cumulative discounted QALYs vs. cumulative costs over a 20-year period for women with cervical cancer undergoing screening for anal dysplasia compared to no screening. Both QALYs and costs are discounted at an annual rate of 3% to reflect their present value. (b) Predicted cumulative costs of screening and treatment for anal cancer over a 20-year period in patients with cervical cancer, comparing screened and unscreened populations. Costs are discounted at an annual rate of 3% to reflect the present value of future expenditures.
Figure 3. (a) Predicted cumulative discounted QALYs vs. cumulative costs over a 20-year period for women with cervical cancer undergoing screening for anal dysplasia compared to no screening. Both QALYs and costs are discounted at an annual rate of 3% to reflect their present value. (b) Predicted cumulative costs of screening and treatment for anal cancer over a 20-year period in patients with cervical cancer, comparing screened and unscreened populations. Costs are discounted at an annual rate of 3% to reflect the present value of future expenditures.
Pathogens 14 01007 g003
Table 1. Model assumptions.
Table 1. Model assumptions.
Annual incidence of cervical cancer in the US attributable to HPV 13,820 [2]
% of women with a history of cervical high-grade dysplasia or microinvasive cancer with anal HPV48.3% [8]
Total number of women with a history of cervical high-grade dysplasia or microinvasive cancer with anal HPV5550
Average age at time of diagnosis of cervical cancer50 [9]
% of women with a history of genital cancer initially having anal ASC-US19.4% [10]
% of women with a history of cervical cancer initially having no anal dysplasia50.8% [10]
% of women with a history of high-grade cervical cytology initially having anal low-grade dysplasia16% [10]
% of women with a history of genital cancer initially having anal high-grade dysplasia3% [10]
% of women with anal HPV and no dysplasia that develop high-grade dysplasia over two years8% [11]
% of women with anal HPV and low-grade dysplasia that develop high-grade dysplasia over two years36% [11]
% of women with anal HPV and ASC-US that develop high-grade dysplasia over two years62% [12]
ACUS cytology equivalents (based on 1-year follow-up cytology in MSM)ACUS represents normal = 58%, ACUS represents LGD = 24%, ACUS represents HSIL = 18%, ACUs represents cancer = 0 [5]
Histological progression and regression (based on 1-year follow-up in MSM)Progression: Normal to LGD = 1.9%, Normal to HGD = 1.78%, Normal to cancer = 0%, LGD to HGD = 16.5%, LGD to anal cancer = 0.05% (estimated), HGD to anal cancer = 3.6%
Regression: LGD to normal = 22.65%, HGD to LGD = 22% (estimated), HGD to normal = 11.36% [5,13]
Annual anal cancer death rate8.96% [14]
Five-year anal cancer death rate29.4% [14]
Annual death rate from cervical cancer11.73% [15]
Five-year death rate from cervical cancer32.6% [15]
Average life expectancy for a female age 4932.95 [16]
Quality of life weight adjustment for anal cancer0.56 [5]
Quality of life weight adjustment after treatment for anal HGD0.9 [5]
Quality of life weight adjustment for cervical cancer0.7 [17]
Quality-adjusted life expectancy woman age 4921.6 [18]
Quality-adjusted life expectancy woman age 49 surviving cervical cancer21.6 × 0.7 = 15.12
Quality-adjusted life expectancy woman age 49 surviving cervical cancer treated for anal HGD15.1 × 0.9 = 13.6
Cost of HPV screen *USD 104 [19]
Cost of anal cytology *USD 72 [19]
Cost of treatment of anal HGD *USD 281 [19]
Cost of high-resolution anoscopy and biopsy *USD 288 [19]
Cost of anal cancer treatment *USD 150,000 [20]
* 2025 Costs are annualized with estimated 2.05% inflation rate in the model.
Table 2. Model estimates of cumulative anal cancers and anal cancer deaths in cervical cancer patients that are screened and treated or not screened and treated for anal HPV and dysplasia.
Table 2. Model estimates of cumulative anal cancers and anal cancer deaths in cervical cancer patients that are screened and treated or not screened and treated for anal HPV and dysplasia.
YearAnal Cancers (Unscreened)Anal Cancers (Screened)Cancer Deaths (Unscreened)Cancer Deaths (Screened)
1119101356182
22951991045399
337327120361066
450734333381706
563740747042605
679146057873476
789150567874755
8101156311,0766048
9113660313,6577428
101236646165259074
11134067619,17910751
12143870221,91912,954
13151072924,72914,984
14161875828,74416,544
15174078029,74418,614
16181780333,14720,039
1719198303794722967
18198785543,44725,856
19180987948,98728,439
20203986351,55331,115
Table 3. Estimates of costs from dynamic modeling for screening for HPV and treatment of anal dysplasia in patients with cervical cancer.
Table 3. Estimates of costs from dynamic modeling for screening for HPV and treatment of anal dysplasia in patients with cervical cancer.
Costs in Unscreened Group (Cancer Care Only)Costs in Screened Group (HPV Screening, Annual Cytology, Treatment of HSIL, and Cancer Care)Cost DifferenceCost per Anal Cancer PreventedCost per Anal Cancer Death PreventedCost per Quality-of-Life Year Saved
5 yearsUSD 304,498,048 USD 235,563,777 USD 68,934,271USD 120,416USD 12,438USD 12,926
10 yearsUSD 1050,234,416 USD 720,133,360 USD 330,101,055USD 117,506USD 10,640USD 11,830
20 yearsUSD 3355,123,274USD 2024,718,550USD 1330,404,723USD 109,222USD 7649USD 9610
Table 4. Results of one-way sensitivity analysis showing the incremental cost per quality-adjusted life year (QALY) gained at varying cure rates of anal high-grade squamous intraepithelial lesions (HSIL) treated with electrocautery.
Table 4. Results of one-way sensitivity analysis showing the incremental cost per quality-adjusted life year (QALY) gained at varying cure rates of anal high-grade squamous intraepithelial lesions (HSIL) treated with electrocautery.
Cure Rate of Anal High-Grade DysplasiaCost per QALY Gained
5 Years		Cost per QALY Gained
10 Years		Cost per QALY Gained
20 Years
0.38USD 3622.22USD 3049.97USD 2049.48
0.48USD 5229.36USD 4514.67USD 3289.81
0.58USD 6834.47USD 5984.13USD 4540.34
0.78USD 10,038.51USD 8937.30USD 7072.34
0.88USD 11,637.40USD 10,420.96USD 8354.02
0.98USD 13,234.15USD 11,909.33USD 9646.29
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Berber, L.; Foy, O.; Cantu, J., Jr.; Ehrenpreis, E.D. Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis. Pathogens 2025, 14, 1007. https://doi.org/10.3390/pathogens14101007

AMA Style

Berber L, Foy O, Cantu J Jr., Ehrenpreis ED. Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis. Pathogens. 2025; 14(10):1007. https://doi.org/10.3390/pathogens14101007

Chicago/Turabian Style

Berber, Lukus, Olivia Foy, Jesus Cantu, Jr., and Eli D. Ehrenpreis. 2025. "Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis" Pathogens 14, no. 10: 1007. https://doi.org/10.3390/pathogens14101007

APA Style

Berber, L., Foy, O., Cantu, J., Jr., & Ehrenpreis, E. D. (2025). Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis. Pathogens, 14(10), 1007. https://doi.org/10.3390/pathogens14101007

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop